The market for erectile dysfunction drugs is on the rise

↑Market size in the third quarter

Gugu·Tadalafil on the rise

The market for erectile dysfunction treatments is recovering.

 

The market size contracted in the aftermath of COVID-19 in the first half, but it rebounded in the third quarter.

 

Generic for Cialis have been largely succeeful.

 

According to IQVIA, a drug research institute on the 10th, the market for erectile dysfunction treatments in the third quarter was ₩28.6 billion, up 1.1% year-on-year.

 

The market for erectile dysfunction drugs declined 4.8% and 0.4%, respectively, compared to the previous year in the first and second quarters, but turned to an upward trend in the third quarter.

 

Quarterly erectile dysfunction treatment market size (Unit: ₩million, Source: IQVIA)

The market for erectile dysfunction treatments showed stable growth every year, but turned downward in the first half of this year.

 

The contraction of the erectile dysfunction treatment market in the first half is analyzed as the aftermath of COVID-19.

 

The industry says that the erectile dysfunction treatment market is vulnerable to external factors such as the epidemic of infectious diseases because the severity is lower than that of chronic diseases such as high blood pressure and diabetes and it is not essential.

 

There is still low recognition that erectile dysfunction is a disease that needs to be treated urgently, which means that changes in the external environment can affect the market growth.

 

Compared to the early days of the spread of COVID-19, the market for erectile dysfunction treatments seems to have recovered as well as people's social activities have become similar to the past.

 

Most of the major leading products were sluggish.

 

Hanmi's PalPal recorded total sales of ₩15.7 billion in the third quarter.

 

PalPal is a generic for Viagra.

 

PalPal accounts for 18.9% of the total erectile dysfunction treatment market.

 

However, the sales volume declined 4.6% compared to last year, and the growth slowed.

 

Cialis’ generic, Cendom by Chong Kun Dang, ranked second place with cumulative sales of ₩7.5 billion in the third quarter, but sales decreased by 3.2% from the previous year.

 

Sales of major erectile dysfunction drugs by item (Unit: ₩million, %, Source: IQVIA)

The original drugs were even more sluggish.

 

Pfizer's Viagra recorded sales of ₩6.4 billion, down 10.7% from the previous year, and Lilly's Cialis, with cumulative sales of ₩4.6 billion, down 4.6% from the same period last year.

 

The cumulative sales of Hanmi’s Gugu in the third quarter rose 13.3% from the previous year to ₩5.8 billion.

 

Kolmar Korea's Kamalafil (generic for Cialis) recorded a growth rate of 20.7%.